4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
CANbridge Pharmaceuticals Inc. (1228) operates in the Biotechnology industry and is headquartered in Suzhou, China with about 41 employees. Its market capitalization is roughly CNY 1 billion. In the fiscal year ended 2025-12-31, 1228 reported CNY 50M in revenue and CNY 15M in net income.
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | CNY 50M | CNY 85M | CNY 103M | CNY 79M |
| Gross Profit | CNY 37M | CNY 54M | CNY 64M | CNY 49M |
| Operating Income (EBIT) | (CNY 92M) | (CNY 340M) | (CNY 365M) | (CNY 450M) |
| Net Income | CNY 15M | (CNY 443M) | (CNY 379M) | (CNY 484M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 165M | CNY 117M | CNY 395M | CNY 702M | — |
| Total Liabilities | CNY 507M | CNY 591M | CNY 435M | CNY 394M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1228 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms